Drug intelligence / Profile preview

DA-3880

Development stage: Phase 1
Lead developer: Dong-A ST
Administration: Intravenous, Subcutaneous

Overview

DA-3880 is a biosimilar of darbepoetin alfa (ARANESP/NESP) developed by Dong-A ST. It is designed for treating anemic patients with chronic renal failure or those undergoing chemotherapy. The drug has been commercialized in Japan after regulatory approval. It functions as an erythropoiesis stimulant by acting as an erythropoietin receptor agonist, helping regulate the growth and maturation of red blood cells.

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on DA-3880.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-3880.

Explore the full profile